RU2019112725A - Композиции и способы для повышения стабильности трансгенов в поксвирусах - Google Patents
Композиции и способы для повышения стабильности трансгенов в поксвирусах Download PDFInfo
- Publication number
- RU2019112725A RU2019112725A RU2019112725A RU2019112725A RU2019112725A RU 2019112725 A RU2019112725 A RU 2019112725A RU 2019112725 A RU2019112725 A RU 2019112725A RU 2019112725 A RU2019112725 A RU 2019112725A RU 2019112725 A RU2019112725 A RU 2019112725A
- Authority
- RU
- Russia
- Prior art keywords
- recombinant poxvirus
- seq
- nucleic acid
- poxvirus
- vntr
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 2
- 108700019146 Transgenes Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 241000700629 Orthopoxvirus Species 0.000 claims 4
- 241000700618 Vaccinia virus Species 0.000 claims 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 241000700663 Avipoxvirus Species 0.000 claims 2
- 108010084313 CD58 Antigens Proteins 0.000 claims 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 108010033276 Peptide Fragments Proteins 0.000 claims 2
- 102000007079 Peptide Fragments Human genes 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Claims (19)
1. Рекомбинантный поксвирус, который является стабильным при последовательном пассировании рекомбинантного поксвируса, где указанный рекомбинантный поксвирус включает первую нуклеиновую кислоту, кодирующую пептид MUC1, имеющий по меньшей мере два вариабельных домена N-концевых повторов (VNTR), где a) порядок расположения нуклеиновых кислот, кодирующих по меньшей мере два домена VNTR MUC1, был изменен, и b) указанные по меньшей мере два домена VNTR были оптимизированы по кодонам, где рекомбинантный поксвирус является стабильным при последовательном пассировании рекомбинантного поксвируса.
2. Рекомбинантный поксвирус по п.1, где первая последовательность нуклеиновой кислоты содержит SEQ ID NO:2.
3. Рекомбинантный поксвирус по п.1, который также включает вторую нуклеиновую кислоту, кодирующую карциноэмбриональный антиген (CEA).
4. Рекомбинантный поксвирус по п.3, где вторая нуклеиновая кислота содержит по меньшей мере одну нуклеотидную замену по меньшей мере в одной повторяющейся нуклеотидной области второй нуклеиновой кислоты, где по меньшей мере одна повторяющаяся нуклеотидная область определена как a) три или более последовательно повторяющихся нуклеотидов G или C и/или b) три или более последовательно повторяющихся нуклеотидов T.
5. Рекомбинантный поксвирус по п.4, где вторая нуклеиновая кислота содержит SEQ ID NO: 13 или SEQ ID NO: 14.
6. Рекомбинантный поксвирус по п.1, где рекомбинантный поксвирус выбран из ортопоксвируса и авипоксвируса.
7. Рекомбинантный поксвирус по п.6, где ортопоксвирус представляет собой вирус осповакцины, являющийся модифицированным вирусом осповакцины Ankara (MVA), который представляет собой MVA-BN.
8. Рекомбинантный поксвирус по п.1, где первая нуклеиновая кислота также содержит по меньшей мере одну нуклеотидную последовательность, кодирующую пептидный фрагмент, выбранный из группы, состоящей из: YLAPPAHGV (SEQ ID NO:24), YLDTRPAPV (SEQ ID NO:25), YLAIVYLIAL (SEQ ID NO:26), YLIALAVCQV (SEQ ID NO:27), YLSYTNPAV (SEQ ID NO:28) и SLFRSPYEK (SEQ ID NO:29).
9. Рекомбинантный поксвирус по п.1, где поксвирус также содержит нуклеиновую кислоту, кодирующую одну или более костимулирующих молекул, выбранных из B7-1, ICAM-1, LFA-3 и их комбинаций.
10. Способ получения рекомбинантного поксвируса, который является стабильным при последовательном пассировании рекомбинантного поксвируса, где указанный способ включает:
получение первой нуклеиновой кислоты, кодирующей белок MUC1, имеющий по меньшей мере два вариабельных домена N-концевых повторов (VNTR), где a) порядок расположения по меньшей мере двух доменов VNTR был изменен, и b) по меньшей мере два домена VNTR были оптимизированы по кодонам, где рекомбинантный поксвирус является стабильным при последовательном пассировании.
11. Способ по п.10, который также включает получение второй нуклеиновой кислоты, кодирующей карциноэмбриональный антиген (CEA).
12. Способ по п.11, где вторая нуклеиновая кислота содержит по меньшей мере одну нуклеотидную замену по меньшей мере в одной повторяющейся нуклеотидной области второй нуклеиновой кислоты, где по меньшей мере одна повторяющаяся нуклеотидная область определена как a) три или более последовательно повторяющихся нуклеотидов G или C и/или b) три или более последовательно повторяющихся нуклеотидов T.
13. Способ по п.10, где рекомбинантный поксвирус выбран из ортопоксвируса и авипоксвируса.
14. Способ по п.13, где ортопоксвирус представляет собой вирус осповакцины, являющийся модифицированным вирусом осповакцины Ankara (MVA), который представляет собой MVA-BN.
15. Способ по п.10, где первая нуклеиновая кислота также содержит по меньшей мере одну нуклеотидную последовательность, кодирующую пептидный фрагмент, выбранный из группы, состоящей из: YLAPPAHGV (SEQ ID NO:24), YLDTRPAPV (SEQ ID NO:25), YLAIVYLIAL (SEQ ID NO:26), YLIALAVCQV (SEQ ID NO:27), YLSYTNPAV (SEQ ID NO:28) и SLFRSPYEK (SEQ ID NO:29).
16. Способ по п.10, где поксвирус также содержит нуклеиновую кислоту, кодирующую одну или более костимулирующих молекул, выбранных из B7-1, ICAM-1, LFA-3 и их комбинаций.
17. Клетка-хозяин, содержащая рекомбинантный поксвирус по п.1.
18. Композиция, содержащая рекомбинантный поксвирус по п.1 и подходящая для введения по гомологичной или гетерологичной схеме первичной бустер-иммунизации.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401035P | 2016-09-28 | 2016-09-28 | |
| US62/401,035 | 2016-09-28 | ||
| PCT/EP2017/074693 WO2018060368A2 (en) | 2016-09-28 | 2017-09-28 | Compositions and methods for enhancing the stability of transgenes in poxviruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019112725A true RU2019112725A (ru) | 2020-10-29 |
| RU2019112725A3 RU2019112725A3 (ru) | 2020-12-09 |
| RU2756534C2 RU2756534C2 (ru) | 2021-10-01 |
Family
ID=60083287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019112725A RU2756534C2 (ru) | 2016-09-28 | 2017-09-28 | Композиции и способы для повышения стабильности трансгенов в поксвирусах |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11052139B2 (ru) |
| EP (1) | EP3518964A2 (ru) |
| JP (1) | JP7062003B2 (ru) |
| KR (1) | KR102605505B1 (ru) |
| CN (1) | CN110198733B (ru) |
| AU (1) | AU2017336269B2 (ru) |
| CA (1) | CA3036799C (ru) |
| IL (1) | IL265539B (ru) |
| RU (1) | RU2756534C2 (ru) |
| WO (1) | WO2018060368A2 (ru) |
| ZA (1) | ZA201901756B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019147869A2 (en) * | 2018-01-24 | 2019-08-01 | Virogin Biotech Canada Ltd | Recombinant viral vaccines |
| WO2020049151A1 (en) * | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020256099A1 (ja) * | 2019-06-21 | 2020-12-24 | 国立大学法人大阪大学 | 外来遺伝子を安定的に保持する人工組換えｒｎａウイルスの作製方法 |
| US12018289B2 (en) | 2019-11-18 | 2024-06-25 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122599A (en) | 1986-08-13 | 1992-06-16 | Molecular Diagnostics, Inc. | CDNAS coding for members of the carcinoembryonic antigen family |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
| CN102409063A (zh) | 2001-12-04 | 2012-04-11 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| GB0212046D0 (en) | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| US8933041B2 (en) | 2003-11-12 | 2015-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | System for treating and preventing breast cancer |
| DK1697399T3 (en) * | 2003-12-12 | 2017-03-06 | Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi | Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| AU2009319336B2 (en) | 2008-11-27 | 2015-03-26 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| WO2013103658A1 (en) * | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| MY194609A (en) | 2012-10-28 | 2022-12-06 | Bavarian Nordic As | Pr13.5 Promoter For Robust T-Cell And Antibody Responses |
| AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
-
2017
- 2017-09-28 AU AU2017336269A patent/AU2017336269B2/en active Active
- 2017-09-28 US US16/337,086 patent/US11052139B2/en active Active
- 2017-09-28 JP JP2019516437A patent/JP7062003B2/ja active Active
- 2017-09-28 CA CA3036799A patent/CA3036799C/en active Active
- 2017-09-28 RU RU2019112725A patent/RU2756534C2/ru active
- 2017-09-28 EP EP17783784.6A patent/EP3518964A2/en active Pending
- 2017-09-28 KR KR1020197012245A patent/KR102605505B1/ko active Active
- 2017-09-28 CN CN201780059549.XA patent/CN110198733B/zh active Active
- 2017-09-28 WO PCT/EP2017/074693 patent/WO2018060368A2/en not_active Ceased
-
2019
- 2019-03-20 ZA ZA2019/01756A patent/ZA201901756B/en unknown
- 2019-03-21 IL IL265539A patent/IL265539B/en unknown
-
2021
- 2021-07-05 US US17/367,528 patent/US11654189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3036799C (en) | 2025-05-13 |
| US20200061174A1 (en) | 2020-02-27 |
| CA3036799A1 (en) | 2018-04-05 |
| AU2017336269A1 (en) | 2019-04-11 |
| US20210338788A1 (en) | 2021-11-04 |
| US11052139B2 (en) | 2021-07-06 |
| CN110198733B (zh) | 2024-04-30 |
| WO2018060368A2 (en) | 2018-04-05 |
| JP7062003B2 (ja) | 2022-05-02 |
| RU2019112725A3 (ru) | 2020-12-09 |
| RU2756534C2 (ru) | 2021-10-01 |
| NZ752275A (en) | 2025-07-25 |
| IL265539A (en) | 2019-05-30 |
| CN110198733A (zh) | 2019-09-03 |
| EP3518964A2 (en) | 2019-08-07 |
| ZA201901756B (en) | 2022-07-27 |
| IL265539B (en) | 2022-03-01 |
| US11654189B2 (en) | 2023-05-23 |
| WO2018060368A3 (en) | 2019-02-07 |
| KR102605505B1 (ko) | 2023-11-22 |
| JP2019528755A (ja) | 2019-10-17 |
| AU2017336269B2 (en) | 2022-06-16 |
| KR20190053272A (ko) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019112725A (ru) | Композиции и способы для повышения стабильности трансгенов в поксвирусах | |
| AU2009319336B2 (en) | Promoters for recombinant viral expression | |
| WO2012172277A4 (en) | Simian adenovirus and hybrid adenoviral vectors | |
| JP2019528755A5 (ru) | ||
| JP2014207903A5 (ru) | ||
| JP2013507935A5 (ru) | ||
| RU2019107976A (ru) | Композиция вакцины | |
| Alharbi | Poxviral promoters for improving the immunogenicity of MVA delivered vaccines | |
| JP2016510989A5 (ru) | ||
| RU2008125815A (ru) | Теломеразная обратная транскриптаза птиц | |
| JP2019535311A5 (ru) | ||
| RU2015115898A (ru) | Новый вирус mva и его применения | |
| US9765305B2 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| JPWO2019226939A5 (ru) | ||
| US20090053256A1 (en) | Poxvirus Methods And Compositions | |
| JP2016082979A5 (ru) | ||
| RU2011137404A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| RU2014129220A (ru) | Новый аттенуированный полиовирус: pv-1 mono-cre-x | |
| Alharbi et al. | Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity | |
| WO2020043869A3 (en) | Methods and compositions for producing a virus | |
| CN107012146B (zh) | 基于位点特异性重组的四膜虫表达载体及其构建和应用 | |
| CN106488983A (zh) | 获得多表位蛋白的方法以及用于体现该方法的dna载体 | |
| RU2021109330A (ru) | Химерные вакцины на основе вирусов родов flavivirus и lyssavirus | |
| Cottingham et al. | Recombination-Mediated Genetic Engineering of a Bacterial Artificial | |
| HK1211622B (zh) | 突变型痘苗病毒株、其用途及其制造方法 |